Knowing stock market today at a glance

Verve Therapeutics Soars 23.31% on Promising Gene-Editing Trial Data

Mover TrackerMonday, Apr 14, 2025 8:48 am ET

1min read

On April 14, 2025, Verve Therapeutics' stock surged by 23.31% in pre-market trading, driven by promising early-stage trial data for its gene-editing therapy.

Verve Therapeutics reported encouraging results from its early-stage study, where a single infusion of VERVE-102 led to significant reductions in blood PCSK9 and LDL-C levels. The mean reduction in LDL-C was 53%, with a maximum reduction of 69%. This therapy employs Verve's proprietary GalNAc-LNP delivery technology, designed to permanently disable the PCSK9 gene in the liver, leading to sustained cholesterol reduction.

The ongoing trial investigates VERVE-102 as a single-course treatment aimed at permanently inactivating the PCSK9 gene, which is a key regulator of cholesterol metabolism. The positive initial data from the Heart-2 Phase 1b clinical trial has bolstered investor confidence in the company's innovative approach to treating high cholesterol.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.